News

The artists Elisabetta Citterio and Claudia Cagliano have created portraits of nearly 60 female researchers from nine countries. Twenty-five of them can be viewed in the "STEM Passion" exhibition until March 12, 2024 in the Rahel Hirsch Center for Translational Medicine Berlin.

A new computer program allows scientists to design synthetic DNA segments that indicate, in real time, the state of cells. Reported by the Gargiulo lab in “Nature Communications”, it will be used to screen for anti-cancer or viral infections drugs, or to improve gene and cell-based immunotherapies.

A tumor often arises when cancer genes multiply. In this process, additional genes act as hitchhikers, potentially creating previously unknown vulnerabilities that open the door to new therapeutic approaches. This finding is reported by a team led by ECRC-scientists Anton Henssen and Jan Dörr in "Cancer Discovery."

Diseases can emerge when the body’s production of serotonin is out of whack. Researchers led by Michael Bader from the Max Delbrück Center have discovered a therapeutic agent that brings down high levels of this hormone. Their start-up, Trypto Therapeutics, aims to develop the drug for the market.

From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research.

Simon Haas has been awarded the Lisec-Artz Prize, endowed with €10,000, for his single-cell analysis of communication between stem and immune cells in blood cancer. The University of Bonn Foundation established this prize to honor outstanding early-career cancer researchers.

Swapping just a single amino acid can play a decisive role in transforming healthy B cells into cancer cells. An international team led by ECRC researcher Stephan Mathas describes in “Nature Communications” how a point mutation in the transcription factor IRF4 profoundly alters gene regulation.

Organoids help researchers understand biological processes in health and in disease. It is, however, difficult to influence the way in which they organize themselves into complex tissues. Now a group led by Nikolaus Rajewsky has found a new way to do so. They report their work in Nature Methods.

Scientists have created a new zebrafish xenograft platform to screen for novel treatments for an aggressive brain tumor called glioblastoma, according to a new study by the Gerhardt and De Smet labs published in “EMBO Molecular Medicine.”

After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently untreatable.